# Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/safety-and-activity-of-the-anti-cd79b-antibody-drug-conjugate-polatuzumab/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Maria Corinna Palanca-Wessels,Myron S. Czuczman,Gilles Salles,Sarit Assouline,Laurie H. Sehn,Ian W. Flinn,Manish R. Patel,Randeep Sangha,Anton Hagenbeek,Ranjana H. Advani,Hervé Tilly,Olivier Casasnovas,Oliver W. Press,Sreeni Yalamanchili,Robert S. Kahn,Randall Dere,Dan Lü,Surai Jones,Cheryl Jones,Yu-Waye Chu,Franck Morschhauser |
| Citations | 335 |
| DOI | 10.1016/s1470-2045(15)70128-2 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2127018518 |
| PMID | 25925619 |
| Type | article |
| Year | 2015 |

## Paper authors

- [Robert S. Kahn](https://scholariq.org/researchers/robert-s-kahn/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)

## Paper topics

- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.